Trial Profile
Axitinib (Ag-013736) As Second Line Therapy For Metastatic Renal Cell Cancer: Axis Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms AXIS
- Sponsors Pfizer
- 16 Feb 2019 Results assessing angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma, presented at the 2019 Genitourinary Cancers Symposium
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
- 12 Oct 2017 Results of pooled data from two phase 3 trial ( A6181034 and Axis trial ) assessing important group differences on the functional assessment of cancer therapy-kidney symptom index disease-related symptoms in patients with metastatic renal cell carcinoma, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.